Injectable Drug Delivery Devices Market Report 2025

The injectable drug delivery devices market size has grown rapidly in recent years. It will grow from $49.59 billion in 2024 to $54.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rapid growth in the elderly population, growth in the number of healthcare facilities, increased healthcare expenditure, growth in the biologics, and increasing awareness of self-administration.

The injectable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $75.28 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing prevalence of chronic diseases, increasing demand for injectable drugs, sudden emergence of severe infections and large numbers of drugs and vaccines in several clinical trial stages. Major trends in the forecast period include focus on developing microneedle-based drug delivery systems, invest in the research and development of self-injectable devices, focus on manufacturing wearable devices, focus on the manufacturing of needle-free injection system, expanding its product line to prefilled syringes, consider improving the digital technology of their devices, focus on manufacturing innovative devices and focus on manufacturing innovative auto-injectors.

The injectable drug delivery devices market is experiencing growth driven by the increasing preference for self-injection devices. These medical devices enable patients to self-administer medication in a home setting and include needle-free, auto, pen, and wearable injectors. Notable examples include BD Physioject, a disposable auto-injector by Becton, Dickinson, and Company, designed for self-injection of drugs in chronic diseases. Companies such as Abbvie, Inc., 3M, Baxter, Gerresheimer AG, and Pfizer Inc. are actively participating in the self-injections market. The advantages of self-injectables and growing awareness of self-administration contribute to the rising demand for such devices, propelling the injectable drug delivery devices market.

The growth of the injectable drug delivery devices market is further fueled by the increasing prevalence of chronic diseases. Injectable drug delivery devices offer a convenient and reliable method for administering medications over extended periods, enhancing patient adherence and improving health outcomes. The National Center for Biotechnology Information (NCBI) projects a significant increase in the global population with chronic diseases, reaching 142.66 million by 2050. This escalating prevalence is a key driver for the injectable drug delivery devices market.

Manufacturers in the injectable drug delivery devices market are placing emphasis on auto-injectors, fully automated, customizable, and reusable devices. Auto-injectors provide patients with control over injection speed, minimizing pain or discomfort. Unilife Corporation's LISA, a reusable auto-injector, offers features such as Bluetooth LE connectivity, Wi-Fi or 3G connectivity, and pre-injection drug warming. The technological advancements and new product launches in injectable drug delivery technology are expected to drive significant market growth.

Major companies in the injectable drug delivery devices market are focusing on developing autoinjector platforms to improve patient compliance, enhance usability, and ensure safer and more effective medication administration. An autoinjector platform is a medical device designed for the automatic and controlled delivery of a specific medication dosage. For example, in May 2022, Jabil Healthcare Inc., a US-based healthcare company, introduced the Qfinity autoinjector platform, a reusable drug delivery device intended for subcutaneous (SC) self-administration of various injectables. The Qfinity autoinjector can manage over 100 injections per device, significantly reducing medical waste compared to single-use devices. This durability promotes a more sustainable approach to drug delivery. It can accommodate 1 mL and 2.25 mL pre-filled disposable cassettes, providing flexibility in drug volume and viscosity, making it suitable for a wide array of medications, including larger-volume and higher-viscosity injectables.

Major companies operating in the injectable drug delivery devices market include Becton, Dickinson and Company, Baxter International, Gerresheimer AG, Catalent, Inc., SkyePharma PLC, Antares Pharma, Pfizer Inc, GE Healthcare, Owen Mumford, Catalent Pharma Solutions, Philips, West Pharmaceutical Services, Inc., Alkermes, Schott AG, UCB, AstraZeneca, Johnson & Johnson, NEARMEDIC PLUS LLC, Pendant Biosciences, Siemens, H&T Presspart, B Braun, Copernicus, Ypsomed AG, 3M Company, Aptar, Congenica Ltd., Julphar, Nemera, Stryker, Roche, Nektar Therapeutics, Eli Lilly, Merck & Co. Inc., Sandoz, Sorrel Medical, Teleflex Medical, Gilero, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, MediPrint Ophthalmics, Medtronic, Novartis, Pharmasyntez, Bayer, Mylan N.V, Aptalis Pharma, Inc., Sanofi, Novo Nordisk, Bilim Pharmaceuticals, Battelle Medical Devices, Caplin Steriles Limited, Abbot, Allergan, Boehringer Ingelheim, Hovione Technology, Jiangsu Delfu Medical Device Co, Ltd., Syqe Medical, Terumo Corporation, Kedalion Therapeutics, Amgen Inc.

North America was the largest region in the injectable drug delivery devices market in 2024. Western Europe was the second-largest region in the global injectable drug delivery devices market. The regions covered in the injectable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the injectable drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Injectable Drug Delivery Devices are medical devices specifically designed to deliver medications directly into the body via injections. These devices are utilized for multiple routes of drug administration, including intravenous, subcutaneous, intradermal, intraperitoneal, and intramuscular.

The primary types of injectable drug delivery devices include conventional injectables, pre-filled syringes, auto-injectors, and pen injectors. Pre-filled syringes come with a fixed needle and contain single-dose vaccines or other medications. These devices find applications in various medical areas such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. Injectable drug delivery devices are utilized by a range of end-users, including hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others.

The injectable drug delivery devices market research report is one of a series of new reports that provides injectable drug delivery devices market statistics, including injectable drug delivery devices industry global market size, regional shares, competitors with injectable drug delivery devices market share, detailed injectable drug delivery devices market segments, market trends, and opportunities, and any further data you may need to thrive in the injectable drug delivery devices industry. This injectable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.